Abstract
Background: The prognostic value of the concentration of serum thymidine kinase 1 (S-TK1) with regard to recurrence in low risk breast cancer patients, 3 months after surgery was evaluated. Patients and Methods: The concentration of S-TK1 in serum was determined in 120 breast cancer patients at the time of surgery and in 67 patients 3 months after surgery, by anti-TK1 chicken IgY antibody, using a dot-blot immuno-assay. The S-TK1 concentration was compared with the serological activity of thymidine kinase (STK) and of carbohydrate antigen (CA 15-3). Results: A statistically significant trend (unadjusted) was found for recurrence (distant or loco-regional) in patients with a higher S-TK1 concentration, as compared with patients with a lower S-TK1 concentration. A multivariate analysis gave the same results. The hazard rate ratio for developing distant and/or loco-regional recurrence in patients with a higher S-TK1 concentration was about six to seven times higher than in patients with a lower S-TK1 concentration. Conclusion: Our results indicate that the S-TK1 concentration is higher in patients developing distant and/or loco-regional recurrence 3 months post-surgery.
Footnotes
-
Abbreviations: ASCO, American Society of Clinical Oncology; CEA, carcino-embryonic antigen; CI, confidence interval; DNA, deoxyribonucleic acid; ECL, enhanced chemiluminescence; ELISA, enzyme-linked immunosorbent assay; ER, oestrogen receptor; HER2/neu, human epidermal growth factor receptor 2; IgG, immunoglobulin G; IgY, immunoglobulin Y; N+, nodal-positive; pN0, nodal-negative; NSCLC, non-small cell lung cancer; HTK1, recombinant human thymidine kinase 1; RIA, radio-immunoassay; STK, activity of thymidine kinase in serum; S-TK1, concentration of thymidine kinase 1 in serum; STO5, Stockholm 5 Clinical Study of Breast Cancer; TK1, thymidine kinase 1; TK2, thymidine kinase 2; TNM, extent of tumour (T), presence of lymph node (N), or distant metastasis (M).
- Received June 30, 2006.
- Accepted September 14, 2006.
- Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved





